Renal Elimination

The kidney removes drug by three processes acting together: filtration at the glomerulus, active secretion into the tubule, and reabsorption back out of it. Filtration is size-dependent and falls away sharply as molecules approach the albumin threshold, so small peptides pass freely into the filtrate. What follows is distinctive. Brush-border peptidases in the proximal tubule degrade most of the filtered peptide, so the kidney clears the compound while very little intact material ever reaches urine.

Strategies for extending peptide half-life are largely strategies for avoiding filtration. PEGylation, albumin binding through a fatty acid, and fusion to an antibody fragment all raise effective hydrodynamic size above the filtration cut-off. The result shows on labels: exenatide, cleared predominantly by the kidney, is not recommended in severe renal impairment, whereas liraglutide and semaglutide, degraded proteolytically throughout the body, carry no renal dose adjustment.

The route predicts whether reduced kidney function raises exposure, and by how much. It also predicts detectability. Anti-doping assays for peptide hormones generally target urine, and their sensitivity depends on how much intact compound survives tubular degradation, which is why detection windows for some peptides are far shorter than their pharmacological effect.

Two inferences fail regularly. A negative urine assay is not evidence that nothing was administered, because most filtered peptide is destroyed before it can be collected. And an estimated glomerular filtration rate does not license a dose adjustment for a compound the kidney does not clear; applying renal thresholds to a proteolytically degraded peptide adjusts the wrong variable.